A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma.

Trial Profile

A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 May 2014

At a glance

  • Drugs Sepantronium bromide (Primary) ; Docetaxel
  • Indications Malignant melanoma
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 05 May 2014 Last checked against M.D. Anderson Cancer Center record.
    • 04 Dec 2012 Planned number of patients changed from 69 to 72 as reported by EudraCT.
    • 31 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top